Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes
dc.contributor.author | Mooranian, Armin | |
dc.contributor.author | Negrulj, Rebecca | |
dc.contributor.author | Al-Sallami, H. | |
dc.contributor.author | Fang, Zhongxiang | |
dc.contributor.author | Mikov, Momir | |
dc.contributor.author | Golocorbin-Kon, S. | |
dc.contributor.author | Fakhoury, M. | |
dc.contributor.author | Watts, G. | |
dc.contributor.author | Matthews, V. | |
dc.contributor.author | Arfuso, Frank | |
dc.contributor.author | Lambros, Amanda | |
dc.contributor.author | Al-Salami, Hani | |
dc.date.accessioned | 2017-01-30T10:45:19Z | |
dc.date.available | 2017-01-30T10:45:19Z | |
dc.date.created | 2014-09-04T20:00:23Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Mooranian, A. and Negrulj, R. and Al-Sallami, H. and Fang, Z. and Mikov, M. and Golocorbin-Kon, S. and Fakhoury, M. et al. 2014. Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes. AAPS PharmSciTech. 16 (1): pp. 45-52. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/5324 | |
dc.identifier.doi | 10.1208/s12249-014-0205-9 | |
dc.description.abstract |
In previous studies, we developed and characterised multicompartmental microcapsules as a platform for the targeted oral delivery of lipophilic drugs in type 2 diabetes (T2D). We also designed a new microencapsulated formulation of probucol-sodium alginate (PB-SA), with good structural properties and excipient compatibility. The aim of this study was to examine the stability and pH-dependent targeted release of the microcapsules at various pH values and different temperatures. Microencapsulation was carried out using a Büchi-based microencapsulating system developed in our laboratory. Using SA polymer, two formulations were prepared: empty SA microcapsules (SA, control) and loaded SA microcapsules (PB-SA, test), at a constant ratio (1:30), respectively. Microcapsules were examined for drug content, zeta potential, size, morphology and swelling characteristics and PB release characteristics at pH 1.5, 3, 6 and 7.8. The production yield and microencapsulation efficiency were also determined. PB-SA microcapsules had 2.6 ± 0.25% PB content, and zeta potential of −66 ± 1.6%, suggesting good stability. They showed spherical and uniform morphology and significantly higher swelling at pH 7.8 at both 25 and 37°C (p < 0.05). The microcapsules showed multiphasic release properties at pH 7.8. The production yield and microencapsulation efficiency were high (85 ± 5 and 92 ± 2%, respectively). The PB-SA microcapsules exhibited distal gastrointestinal tract targeted delivery with a multiphasic release pattern and with good stability and uniformity. However, the release of PB from the microcapsules was not controlled, suggesting uneven distribution of the drug within the microcapsules. | |
dc.publisher | AAPS | |
dc.subject | diabetes mellitus | |
dc.subject | artificial-cell microencapsulation | |
dc.subject | anti-inflammatory | |
dc.subject | probucol | |
dc.subject | antioxidant | |
dc.subject | type 2 diabetes | |
dc.title | Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes | |
dc.type | Journal Article | |
dcterms.source.issn | 1530-9932 | |
dcterms.source.title | AAPS PharmSciTech | |
curtin.note |
The final publication is available at Springer via | |
curtin.department | School of Pharmacy | |
curtin.accessStatus | Open access |